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Abstract: Background: Observational studies assessing the cardiovascular adverse effect of naproxen have had conflict-
ing results. It is not clear whether variation in population characteristics between studies may explain some of this dis-
crepancy. 
Objective: To determine whether changes in patient characteristics of naproxen users occurred between 1999 and 2004 in 
Québec, Canada and to examine whether these temporal changes were accompanied by changes in estimates of naproxen-
related hospitalizations for gastrointestinal (GI) ulcers and myocardial infarction, using provincial health services admin-
istrative databases. 
Methods: Demographic, pharmaceutical and physician billing records of patients 65 years and older, who received 
naproxen or acetaminophen prescriptions between 1999 and 2004 were used. Two identical cohort studies, labeled Study 
1 and Study 2 were conducted and their results were compared. One study was confined to the time period 1999-2001 and 
the other to 2002-2004. Patient characteristics at index date (the date of the first naproxen or acetaminophen prescription 
during the corresponding period) were compared between the study cohorts in naproxen and acetaminophen users, respec-
tively, and within each study cohort between naproxen and acetaminophen users, using logistic regression models. Cox 
regression models with time dependent exposure were used to assess the association between naproxen vs acetaminophen 
and hospitalizations for GI events or AMI, respectively within each study. Results were then compared between the two 
studies. 
Results: Study 1 (1999-2001) cohort included 240,568 patients (205,238 acetaminophen and 35,330 naproxen) and Study 
2 (2002-2004) cohort included 213,802 patients (193,918 acetaminophen and 19,884 naproxen). Patient characteristics of 
naproxen and acetaminophen users differed between the two studies. Naproxen users in Study 2 vs Study 1 were slightly 
younger, less likely to be females, less likely to have concomitant GI disease, less likely to have osteoarthritis and other 
co-morbidities and more likely to have used proton pump inhibitors, antihypertensive agents, anticoagulants, clopidogrel 
and aspirin. In general, similar changes in patient characteristics were observed in acetaminophen users between the two 
study cohorts. Compared to acetaminophen (without aspirin), the estimates of the GI risks with naproxen whether, used 
with or without aspirin, were significantly higher in Study 2 vs Study 1 [Hazard Ratio (HR) (95% CI): 4.94 (3.48, 7.02)] 
vs [2.22 (1.62, 3.06)], naproxen with aspirin [4.94 (2.93, 8.33) vs 2.47 (1.48, 4.12)], and acetaminophen and aspirin: [2.31 
(1.89, 2.82) vs 1.46 (1.20, 1.77)]. The estimate of the AMI risk with naproxen also seemed to be higher in Study 2 vs 
Study 1, however the increase was not statistically significant [HR (95% CI) in the naproxen group: 1.18 (0.83, 1.67) in 
Study 1 vs 0.94 (0.70, 1.25) in Study 2], naproxen with aspirin. [1.44 (0.95, 2.18) vs 1.05 (0.68, 1.61)]; and acetamino-
phen and aspirin. 1.15 (1.01, 1.30) vs 1.10 (0.97, 1.26). 
Conclusion: Variation in patient characteristics in naproxen users was observed between 1999 and 2004. This variation 
was likely to be accompanied by a variation in patient pre-disposition to GI events that may explain the increase in esti-
mates of naproxen-related GI adverse events observed during this period.  
INTRODUCTION 
  Traditional non-steroidal anti-inflammatory drugs (tNSAIDs) 
effectively relieve acute and chronic pain and reduce inflam-
mation [1-3]. However, important gastrointestinal (GI) and 
cardiovascular (CV) adverse events can occur with the use  of 
these  drugs [4-6]. The  association  between  tNSAIDS 
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and GI adverse events is well established [7]. Serious 
tNSAID-associated GI adverse events, including gastroduo-
denal erosions and life-threatening complications such as 
bleeding and perforation in the upper GI tract are hard to 
predict, since they are not often preceded by warning symp-
toms [8]. To prevent these complications, it is recommended 
to use a gastroprotective agent (GPA) [misoprostol, hista-
mine2-receptor antagonists (H2RAs), or proton pump inhibi-
tor (PPI)] with tNSAIDs [9, 10]. The prescription of GPA 
with tNSAID reduces the risk of GI adverse events associ-
ated with these medications, but does not eliminate it and 
considerably increases patient management cost [11]. Cy-2    The Open Rheumatology Journal, 2009, Volume 3  Rahme et al. 
clooxygenase (COX)-2 selective NSAIDs have been shown 
to have an improved GI safety profile as compared to 
tNSAIDs [4, 12]. However, some clinical trials have found 
that some COX-2 selective NSAIDs may have serious CV 
adverse events [4, 13-15]. Some studies have also suggested 
that the CV risk is not unique to COX-2 selective NSAIDs, 
but may be common to all NSAIDs [16]. Naproxen is among 
the tNSAIDs that are frequently used in Québec [17]. At 
least one clinical trial has found that naproxen may have an 
improved CV safety profile over some COX-2 selective 
NSAIDs [4]. Patients in this trial were not allowed to use 
aspirin and it was suggested that the use of aspirin with 
COX-2 inhibitors in the patients at risk of CV adverse events 
may decrease this risk [4]. Clinical trials, specifically de-
signed to study the CV adverse events with naproxen or with 
the combination of naproxen and aspirin, are lacking. The 
health care community has relied on observational studies to 
assess these events in real life settings. Several studies have 
been conducted in various countries and provinces, but re-
sults are conflicting [18-20]. Reasons explaining differences 
in results between studies have not been delineated. The 
characteristics of patients using naproxen in clinical practice 
may differ substantially from those of patients that are in-
cluded in clinical trials from which sick patients are usually 
excluded. These characteristics may also differ between 
countries and between provinces or states within the same 
country, because of different drug regulation policy or mar-
keting strategies. The characteristics of the population using 
a certain medication may also change overtime within the 
same province or state, when knowledge about the medica-
tion changes or when a new medication is marketed. 
  We used health services administrative databases to de-
termine whether changes in patient characteristics occurred 
among naproxen and acetaminophen users in 2002-2004 vs 
1999-2001 in Québec, Canada, and to examine whether these 
temporal changes were accompanied by changes in estimates 
of naproxen vs acetaminophen-related hospitalizations for GI 
events and acute myocardial infarction (AMI). 
METHODS 
Data Sources 
  Data for this study were obtained from the Québec health 
services administrative databases administered by the Régie 
de l’assurance maladie du Québec (RAMQ). In Québec, 
Canada, all persons aged 65 years or older, who received 
social assistance, and those who do not have private drug 
insurance through their employer since 1997 are eligible for 
coverage, under the drug reimbursement program adminis-
tered by RAMQ. The RAMQ prescription drugs database 
contains information on all outpatient dispensed prescrip-
tions, including drug name, dispensation date, dosage, form, 
duration, and quantity of the drug dispensed. Drugs dis-
pensed to patients during stays in the hospitals or public 
nursing homes, and over-the-counter drugs are not included 
in the database. Coverage for outpatient and inpatient physi-
cian services is universal. The RAMQ physician claims da-
tabases contained information on physician encounters, in-
cluding date of the visit, place (outpatient clinic, or hospital), 
encrypted identification number of the physician, specialty 
of the physician, procedure performed (e.g. endoscopy) and 
diagnosis coded, using the International Classification of 
Diseases, 9
th Revision (ICD-9). The Québec  hospital dis-
charge summary database provides information on all hospi-
tal admissions for the entire province. This information in-
cludes primary and up to 15 secondary diagnoses (coded 
according to the ICD-9 codes during the study period), ad-
mission and discharge dates, and procedures done. These 
databases are linkable through a unique patient identifier. 
Naproxen, aspirin and acetaminophen were available during 
the study period to all covered patients without any restric-
tion to their use. Acetaminophen and aspirin were also avail-
able over the counter. 
  Permission from the Government of Québec ethics com-
mittee, the Commission d’accès à l’information, was ob-
tained to use the data. 
Design and Data 
  We conducted and compared the results of two separate 
population-based retrospective cohort studies, using the 
same design, methodology and data source, but covering two 
different time periods, January 1999 -December 2001 (Study 
1) and January 2002- December 2004 (Study 2), respec-
tively. In both studies, we used RAMQ and hospital admis-
sion records of patients aged 65 years or older, who filled at 
least one prescription for naproxen or acetaminophen during 
the corresponding study period. Hospitalizations for upper 
GI events (ulcer, bleeding or perforation) and for AMI dur-
ing that period were identified from the hospital discharge 
summary database. 
Inclusion/Exclusion Criteria 
  Two cohorts, one for each study, were constructed in a 
similar manner. The date of the first filled prescription for 
naproxen or acetaminophen during each study period, re-
spectively, was considered as the patient’s index date for the 
corresponding cohort. New users in each cohort were defined 
as patients, who had not filled a prescription for the study 
medications in the year prior to the index date. Patients with 
a GI or AMI hospitalization, as defined below, in the year 
prior to the index date were excluded. Patients who filled 
prescriptions for both naproxen and another NSAID or 
naproxen and acetaminophen on the index date were also 
excluded. 
Outcome Measure 
  The outcomes of interest were the first hospitalization for 
an upper GI event (ulcer, bleeding or perforation in the 
stomach or duodenum) or for AMI during the corresponding 
study period. Hospitalization was considered only for the 
patients who were discharged from acute care hospitals with 
GI event (ICD-9 codes: 531.x, 532.x, 533.x, 534.x, 578.x) or 
AMI (ICD-9 code 410.x), recorded as the most responsible 
diagnosis (primary discharge diagnosis). 
Follow-Up 
 In  each  cohort, patients were followed from their index 
date to the earliest of: an upper GI hospitalization, an AMI 
hospitalization, death or the end of the corresponding study 
period. 
Drug Exposures 
  Exposure to a study drug was defined as the number of 
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addition to a grace period of 25% of this number. A hospi-
talization for GI or AMI event that occurred during an expo-
sure period was attributed to that period. Events that oc-
curred during a period overlapping two study drugs were 
attributed to the drug dispensed last. This assumes that the 
patient stopped the use of the first drug at the date of the 
second drug dispensing. This assumption was checked in a 
sensitivity analysis. Exposure episodes, where two different 
study drugs were dispensed on the same day were excluded 
from the analyses. The use of aspirin may affect both GI and 
CV adverse events, as we had found in a previous study that 
the utilization of aspirin increased significantly among 
NSAID and acetaminophen users between 1999 and 2004 
[21], we separated exposure episodes into those with and 
those without aspirin. Therefore, exposure episodes were 
classified into four categories: naproxen and aspirin, aceta-
minophen and aspirin, naproxen alone, and acetaminophen 
alone. A prescription of acetaminophen was classified as 
acetaminophen and aspirin, if the patient filled an aspirin 
prescription, which supplied days overlapped those for 
acetaminophen. The naproxen and aspirin category was de-
fined in a similar manner. Patients in these categories were 
termed “users of aspirin”. All exposure episodes occurred 
during follow-up were considered in the analyses. Therefore, 
patients could contribute time to more than one exposure 
category. 
Patient Characteristics 
  Patient characteristics that were assessed at the index 
date were: age and gender; prescription for NSAIDs, use of 
GPA, antihypertensive agents, antidiabetic agents, lipid low-
ering agents or vasodilators in the prior year; prescriptions 
for corticosteroids, anticoagulants, clopidogrel or aspirin in 
the prior three months; GI events in the prior year (upper GI 
investigations (endoscopy, Barium swallow) and diagnoses 
of ulcer in the upper GI tract), ischemic heart disease, con-
gestive heart failure, cerebrovascular disease, peripheral vas-
cular disease, chronic or acute renal failure, anemia or blood 
diseases, chronic obstructive pulmonary disease (COPD), 
and osteoarthritis or rheumatoid arthritis. 
Statistical Analyses 
  Patient characteristics at the index date were compared 
between naproxen and acetaminophen patients within each 
cohort, respectively, and between the two cohorts within 
naproxen and acetaminophen patients, respectively, using 
logistic regression models. In each study, the GI and AMI 
risks with naproxen used either with or without concomitant 
aspirin were compared to those with acetaminophen (without 
concomitant aspirin), using multivariable Cox regression 
models with time-dependent exposures and fixed baseline 
patient characteristics. Times of non-exposure were not in-
cluded in the model to facilitate the analysis. Discontinuous 
time intervals removed the subjects from the risk sets during 
the time of non-exposure [22]. Sensitivity and sub-group 
analyses were conducted in each study. In the sensitivity 
analysis, events that occurred during overlapping times were 
attributed to the drug dispensed first and in sub-group analy-
ses all analyses were repeated considering only ‘New users’. 
All statistical analyses were performed using SAS for Linux, 
version 9.2 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
Patient Characteristics at Index Date 
  In Study 1 (1999-2001), the cohort included 240,568 
patients (205,238 acetaminophen and 35,330 naproxen), and 
in Study 2 (2002-2004), the cohort included 213,802 patients 
(193,918  acetaminophen and 19,884 naproxen). Patient 
characteristics are displayed in Table 1 by cohort and study 
drug used at index date. Results of the logistic regression 
models, comparing patient characteristics between cohorts 
within users of each study drug, are also displayed in Table 
1. As compared to patients who used naproxen in 1999-
2001, those who used it in 2002-2004 were 16% less likely 
to be females, 38% less likely to have had an outpatient di-
agnosis of GI ulcer, but 75% more likely to have used a PPI 
at the index date. They were also more likely to have filled 
prescriptions for PPIs (93%), antihypertensive agents (37%), 
anticoagulants (47%), clopidogrel (79%), and aspirin (57%) 
in the prior year; less likely to have had a diagnosis with 
osteoarthritis (27%), and CV diseases or COPD in the prior 
year (Table 1). In general, similar differences were observed 
among acetaminophen users across the two cohorts (Table 
1). Table 2 displays the results of the logistic regression 
models comparing patient characteristics between aceta-
minophen and naproxen users within each cohort among all 
patients and among new users, respectively. In both cohorts, 
patients using naproxen were younger, included fewer fe-
males, had less GI or CV diseases and more of them had a 
diagnosis of arthritis. 
Naproxen, Acetaminophen and Aspirin Utilization in 
Follow-Up 
  The total number of prescriptions filled by study patients 
during follow-up and the number of patient-years (p-years) 
of exposure from each exposure category are reported in 
Table 3. Patients in the first cohort filled 1,223,017 prescrip-
tions for acetaminophen (only), 549,497 prescriptions for 
acetaminophen and aspirin, 134,991 prescriptions for 
naproxen (only), and 34,008 prescriptions for naproxen and 
aspirin, while patients in the second cohort filled 1,238,624 
prescriptions for acetaminophen (only), 826,057 prescrip-
tions for acetaminophen and aspirin, 90,045 prescriptions for 
naproxen (only), and 34,537 prescriptions for naproxen and 
aspirin. 
Hospitalizations for Gastrointestinal Events 
  Unadjusted rates of GI hospitalizations seemed to be 
higher for naproxen users in Study 2 vs Study 1 (6.57/1000 
p-years in 1999-2001 and 8.28/1000 p-years in 2002-2004) 
and lower in acetaminophen users (4.46/1000 p-years and 
3.07/1000 p-years, respectively) (Table 3). Results from the 
time-dependent Cox regression models, comparing the ad-
justed hazard ratios (HR) of GI hospitalization between the 
exposure categories are shown in Table 4. Compared to pa-
tients using acetaminophen (without aspirin), the adjusted 
HR [95% confidence interval (CI)] of hospitalization for 
upper GI events was higher in Study 2 vs Study 1 among 
users of naproxen without aspirin 4.94 (3.48, 7.02) vs 2.22 
(1.62, 3.06). This difference was statistically significant as 
evidenced  by the non-overlapping  confidence intervals. The  
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HR of GI hospitalizations was also significantly higher in 
Study 2 vs Study 1 among users of acetaminophen with aspi-
rin 2.31 (1.89, 2.82) vs 1.46 (1.20, 1.77), but not among us-
ers of naproxen with aspirin 4.49 (2.93, 8.33) vs 2.47 (1.48, 
4.12), although results pointed to that direction. 
Hospitalizations for Acute Myocardial Infarction 
  Unadjusted rates of hospitalizations for AMI seemed to 
be similar in Study 2 vs Study 1 among naproxen users, al-
though results pointed to a possible small increase in Study 2 
(Table 3). Results from the time-dependent Cox regression 
models, comparing the adjusted HR of AMI hospitalizations 
between the exposure categories are shown in Table 4. Com-
pared to patients using acetaminophen (without aspirin), the 
adjusted HR (95% CI) of AMI hospitalization was also not 
statistically different between Study 2 and Study 1 in all 
other exposure categories, although results pointed to a pos-
sible small increase in Study 2 (Table 4). 
  Sensitivity analyses and subgroup analyses conducted in 
new users revealed similar results (data not shown). 
DISCUSSION 
  This study compared the estimates of the risks of hospi-
talizations for upper GI events and AMI among naproxen 
and acetaminophen users, obtained from two identical stud-
ies conducted separately in the same geographical area over 
two different time-periods. Patient characteristics of users of 
these medications differed between studies and the risks of 
GI hospitalizations among naproxen vs acetaminophen users 
seemed to be higher in Study 2 vs Study 1. As we used the 
Table 1.  Comparison of Patient Characteristics at Index Dates Between Study 2 vs Study 1 Cohorts Using Logistic Regression Models 
 
Acetaminophen Naproxen    
Study 1   Study 2  OR (95% CI)  Study 1  Study2  OR (95% CI) 
Total No. of patients  205,238  193,918  -  35,330  19,884  - 
Female% 
Age at index date (± SD) 
62.7 
76.5 ± 7.1 
62.0 
77.0 ± 7.2 
0.95 (0.94, 0.96) 
1.01 (1.01, 1.01) 
57.6 
72.8 ± 5.7 
52.8 
72.5 ± 5.6 
0.84 (0.81, 0.88) 
0.99 (0.99, 1.00) 
NSAIDs in prior year  13.7  3.8  0.26 (0.25, 0.27)  36.4  22.4  0.54 (0.52, 0.56) 
GI test in prior year % 
Peptic ulcer disease 
GPA in prior year 
PPI 
H2-RA 
Misoprostol 
GPA at index date % 
PPI 
H2-RA 
Misoprostol 
9.8 
2.3 
 
18.7 
12.5 
1.0 
 
5.0 
2.8 
0.1 
8.6 
1.9 
 
29.4 
5.7 
0.2 
 
9.8 
1.4 
0.0 
0.75 (0.74, 0.77) 
0.79 (0.75, 0.83) 
 
1.86 (1.83, 1.90) 
0.45 (0.44, 0.46) 
0.31 (0.27, 0.35) 
 
1.50 (1.46, 1.54) 
1.00 (0.95, 1.06) 
0.83 (0.58, 1.20) 
5.2 
1.2 
 
11.8 
8.5 
2.3 
 
6.1 
2.3 
2.6 
4.2 
0.7 
 
18.3 
3.7 
0.5 
 
11.6 
1.2 
0.5 
0.71 (0.65, 0.78) 
0.62 (0.51, 0.76) 
 
1.93 (1.82, 2.03) 
0.47 (0.43, 0.51) 
0.48 (0.39, 0.60) 
 
1.75 (1.64, 1.87) 
0.88 (0.76, 1.03) 
0.28 (0.23, 0.35) 
Comorbidities% 
Anemia blood disease 
Renal failure (acute/chronic) 
COPD 
Osteoarthritis 
Rheumatoid arthritis 
 
8.0 
2.6 
10.5 
14.4 
1.6 
 
8.7 
3.5 
8.9 
13.9 
1.5 
 
1.05 (1.03, 1.08) 
1.15 (1.11, 1.20) 
0.82 (0.80, 0.84) 
1.14 (1.12, 1.16) 
1.04 (0.98, 1.10) 
 
4.1 
0.9 
6.4 
17.1 
2.7 
 
3.9 
1.0 
5.0 
12.7 
2.1 
 
0.97 (0.89, 1.07) 
1.00 (0.82, 1.20) 
0.76 (0.70, 0.82) 
0.81 (0.77, 0.85) 
1.03 (0.90, 1.16) 
Prior* CV risk % 
CHF 
IHD 
Acute CVD 
PVD 
 
7.3 
21.7 
3.5 
5.1 
 
7.1 
22.5 
3.7 
4.7 
 
0.78 (0.76, 0.80) 
0.88 (0.86, 0.89) 
0.72 (0.69, 0.74) 
0.77 (0.75, 0.80) 
 
2.6 
14.0 
1.4 
2.9 
 
2.0 
12.9 
1.1 
2.4 
 
0.71 (0.62, 0.81) 
0.82 (0.77, 0.87) 
0.53 (0.44, 0.63) 
0.73 (0.65, 0.82) 
Prior medication use% 
Antidiabetic 
Antihypertensive 
Lipid lowering agents 
SSRI 
Vasodilator 
Medication use in prior 90 days 
Anticoagulant 
Corticosteroid 
Clopidogrel 
Aspirin 
 
9.8 
49.6 
16.3 
6.1 
20.6 
 
8.7 
6.2 
0.7 
27.7 
 
17.0 
60.0 
19.3 
5.7 
20.1 
 
11.5 
6.3 
3.9 
35.9 
 
1.05 (1.03, 1.07) 
1.43 (1.41, 1.45) 
1.13 (1.11, 1.15) 
0.92 (0.89, 0.94) 
0.73 (0.72, 0.74) 
 
1.50 (1.46, 1.53) 
1.08 (1.05, 1.11) 
6.02 (5.67, 6.40) 
1.53 (1.51, 1.55) 
 
10.2 
37.7 
16.9 
3.5 
12.1 
 
1.8 
4.5 
0.2 
19.1 
 
11.1 
45.2 
17.5 
2.9 
9.8 
 
2.4 
4.4 
1.3 
25.2 
 
0.99 (0.93, 1.05) 
1.37 (1.31, 1.42) 
0.95 (0.90, 1.00) 
0.83 (0.75, 0.92) 
0.67 (0.62, 0.72) 
 
1.47 (1.29, 1.68) 
1.09 (0.99, 1.20) 
7.97 (5.97, 10.64) 
1.58 (1.50, 1.65) 
*Identified in the prior year. 
Abbreviations: GI= gastrointestinal; GPA= gastroprotective agent; PPI= proton pump inhibitor; H2RA= histamine-2 receptor antagonist; SSRI= serotonin reuptake inhibitor; COPD= 
chronic obstructive pulmonary disease; CHF= congestive heart failure; IHD= ischemic heart disease; CVD= cerebrovascular disease; PVD= peripheral vascular disease; CV= car-
diovascular disease; OR= odds ratio; CI= confidence interval; SD= standard deviation. Naproxen-Associated Adverse Events  The Open Rheumatology Journal, 2009, Volume 3    5 
same methodology, adjusted for all known confounders that 
could be measured from the database in both studies, we 
hypothesized that the increase in risk estimates observed in 
Study 2 among naproxen users is likely to be attributable to a 
higher pre-disposition to GI events of naproxen users in that 
study and/or a lower pre-disposition in acetaminophen users. 
This could be possible, if for example more patients at 
higher risk of GI events used naproxen in the second period, 
because of a perception of a better AMI safety with the drug 
and/or if more patients at high risk of GI events switched 
from acetaminophen to a COX-2 inhibitor, however, these 
hypotheses cannot be confirmed from the current data. 
Nonetheless, these results suggest that estimates from obser-
vational studies assessing drug-related adverse events are 
affected by differences in study patients’ characteristics, in 
particular those that cannot be measured and for adjusted in 
multivariable models such as disease severity and pre-
disposition to the adverse event. 
  Published studies assessing the association between 
naproxen use and GI events have found an increased risk 
with naproxen either when compared to no-use [27], aceta-
minophen [28] or other NSAIDs, [29, 30] however, the 
magnitude of this increase has varied between the studies 
[27, 31, 32]; some reporting a two-fold increase [27], while 
others reporting a 9-fold increase [31]. In our study, we 
Table 2.  Logistic Regression Models Comparing Patient Characteristics of those Using Naproxen vs Acetaminophen at the Index 
Date in the Two Study Cohorts 
 
Study 1  Study 2 
All Patients 
N = 240,568 
New Users 
N =144,059 
All Patients 
N = 213,802 
New Users 
N =132,381 
 
OR (95% CI) 
Female 
Age at index date 
0.62 (0.62, 0.63) 
0.92 (0.92, 0.92) 
0.75 (0.73, 0.76) 
0.91 (0.91, 0.91) 
0.59 (0.58, 0.60) 
0.91 (0.91, 0.91) 
0.68 (0.66, 0.69) 
0.90 (0.90, 0.90) 
NSAIDs in prior year  5.70 (5.63, 5.78)    14.72 (14.48, 14.96)   
GI test in prior year 
Peptic ulcer disease 
GPA in prior year 
PPI 
H2RA 
Misoprostol 
GPA at index date 
PPI 
H2RA 
Misoprostol 
0.76 (0.74, 0.78) 
0.81 (0.77, 0.85) 
 
0.52 (0.51, 0.53) 
0.58 (0.57, 0.60) 
0.77 (0.75, 0.80) 
 
1.52 (1.48, 1.56) 
1.14 (1.10, 1.18) 
9.82 (9.28, 10.38) 
0.74 (0.70, 0.77) 
0.73 (0.66, 0.80) 
 
0.56 (0.54, 0.58) 
0.70 (0.67, 0.73) 
0.56 (0.44, 0.72) 
 
1.60 (1.53, 1.68) 
0.94 (0.87, 1.01) 
12.55 (11.21, 14.05) 
0.70 (0.67, 0.72) 
0.70 (0.65, 0.76) 
 
0.52 (0.51, 0.53) 
0.56 (0.54, 0.58) 
0.79 (0.72, 0.87) 
 
1.55 (1.51, 1.59) 
0.96 (0.90, 1.02) 
12.80 (10.96, 14.96) 
0.70 (0.66, 0.74) 
0.54 (0.47, 0.62) 
 
0.62 (0.60, 0.64) 
0.73 (0.68, 0.79) 
0.86 (0.58, 1.29) 
 
1.79 (1.72, 1.86) 
0.99 (0.86, 1.13) 
15.52 (10.87, 22.15) 
Comorbidities 
Anemia/blood disease 
Renal failure 
COPD 
Osteoarthritis 
Rheumatoid arthritis 
 
0.77 (0.75, 0.80) 
0.58 (0.55, 0.62) 
0.65 (0.63, 0.66) 
0.73 (0.72, 0.74) 
1.74 (1.69, 1.79) 
 
0.75 (0.71, 0.78) 
0.49 (0.44, 0.54) 
0.68 (0.65, 0.71) 
1.33 (1.33, 1.37) 
1.41 (1.30, 1.54) 
 
0.78 (0.75, 0.80) 
0.43 (0.40, 0.47) 
0.67 (0.65, 0.70) 
0.72 (0.71, 0.74) 
1.80 (1.73, 1.87) 
 
0.74 (0.70, 0.79) 
0.51 (0.46, 0.57) 
0.63 (0.59, 0.66) 
1.07 (1.03, 1.11) 
1.45 (1.30, 1.61) 
Prior CV risk factors 
CHF 
IHD 
Acute CVD 
PVD 
 
0.90 (0.88, 0.93) 
0.96 (0.94, 0.98) 
0.73 (0.70, 0.77) 
0.76 (0.74, 0.79) 
 
0.68 (0.64, 0.73) 
0.86 (0.83, 0.89) 
0.51 (0.47, 0.55) 
0.70 (0.66, 0.75) 
 
0.86 (0.82, 0.90) 
0.92 (0.90, 0.94) 
0.55 (0.52, 0.59) 
0.74 (0.70, 0.77) 
 
0.81 (0.75, 0.87) 
0.91 (0.87, 0.94) 
0.38 (0.35, 0.42) 
0.66 (0.62, 0.71) 
Prior* medication use 
Antidiabetic 
Antihypertensive 
Lipid lowering agents 
SSRI 
Vasodilator 
Medication use in prior 90 days 
Anticoagulant 
Corticosteroid 
Clopidogrel 
Aspirin 
 
0.69 (0.68, 0.70) 
0.77 (0.76, 0.78) 
0.93 (0.91, 0.94) 
0.55 (0.53, 0.56) 
0.77 (0.76, 0.79) 
 
0.31 (0.30, 0.32) 
0.84 (0.82, 0.86) 
0.86 (0.72, 1.02) 
0.71 (0.70, 0.72) 
 
0.66 (0.64, 0.69) 
0.88 (0.86, 0.90) 
1.10 (1.07, 1.13) 
0.57 (0.54, 0.60) 
1.00 (0.97, 1.04) 
 
0.29 (0.27, 0.30) 
0.84 (0.80, 0.88) 
0.47 (0.39, 0.56) 
0.72 (0.70, 0.74) 
 
0.64 (0.64, 0.66) 
0.74 (0.73, 0.76) 
0.95 (0.93, 0.93) 
0.49 (0.47, 0.51) 
0.77 (0.75, 0.79) 
 
0.34 (0.32, 0.35) 
0.90 (0.87, 0.93) 
0.57 (0.54, 0.61) 
0.69 (0.68, 0.71) 
 
0.66 (0.63, 0.68) 
0.85 (0.83, 0.87) 
1.02 (0.98, 1.05) 
0.49 (0.46, 0.52) 
0.94 (0.90, 0.98) 
 
0.25 (0.23, 0.26) 
0.85 (0.80, 0.90) 
0.47 (0.43, 0.51) 
0.71 (0.69, 0.73) 
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reporting a 9-fold increase [31]. In our study, we found a 
acetaminophen users in Study 1, and a 5-fold increase in 
Study 2. Observational studies assessing the association be-
tween naproxen and CV adverse events have also had con-
flicting results [16, 18, 20, 23-26]. Many of these studies 
have found a beneficial CV effect of naproxen when com-
pared to other NSAIDs [16, 18, 23], while others did not find 
such effect when naproxen was compared to no or remote 
use of NSAID, [25, 26] with some finding an increased risk 
with naproxen [20, 24]. 
  While many studies have discussed the possible presence 
of channeling bias occurring when higher risk patients are 
more likely to be prescribed a specific drug [33, 34], and 
methods to reduce this bias have been recommended; [34] no 
previously published study has documented the magnitude of 
variation in results over time in the same population. Re-
cently, one paper investigating the risk of AMI with 
NSAIDs, showed that adjustments for the dose and pattern of 
utilization of the medications (number of previous prescrip-
tions, duration, and number of gaps between previous pre-
scriptions) significantly affect the results [35]. In our analy-
ses, results between the two studies remained different, when 
we considered only ‘New users’ (those who did not have any 
NSAID or acetaminophen prescription in the previous year) 
(data not shown). Therefore, previous use of NSAID cannot 
solely account for the difference in results observed between 
the two studies. 
  Our two studies were conducted using large, population-
based, well-validated medical databases that included pa-
tients with multiple GI and AMI risk factors who are typi-
cally excluded from clinical trials. We used identical designs 
and methods in both studies to rule out the possibility of any 
change related to the methodology used. Nonetheless, our 
studies have limitations. First, misclassification may have 
occurred in the identification of some co-morbidity that re-
lied on physician diagnoses such as COPD, renal failure, 
alcohol or drug abuse, osteoarthritis, and rheumatoid arthri-
tis. However, these misclassifications, if they occurred, were 
likely to be non-differential between studies and between 
study medications within each study and are unlikely respon-
sible for the important change in results observed between 
the two studies. Second, differences may exist between pa-
tients prescribed acetaminophen and those prescribed 
naproxen, based on variables that were not available in the 
Table 3.  Total Number of Prescriptions and Crude Rates of GI and AMI Hospitalizations 
 
  No. of 
Patients 
No. of 
Prescriptions 
Total Dura-
tion (Years) 
No. of GI Hospitalizations  
(Rate /1000 p-Years) 
No. of AMI Hospitalizations 
(Rate /1000 p-Years) 
Study 1 
Acetamin  153,638  1,223,017  62,974  281 (4.46)  585 (9.28) 
Naproxen  29,056  134,991  7,904  49 (6.20)  52 (6.57) 
Acetamin + aspirin  51,600  549,497  29,412  181 (6.15)  400 (13.59) 
Naproxen + aspirin  6,274  34,008  1,957  16 (8.17)  22 (11.24) 
Study 2 
Acetamin  129,429  1,238,624  62,826  193 (3.07)  559 (8.89) 
Naproxen  15,200  90,045  5,191  43 (8.28)  35 (6.74) 
Acetamin + aspirin  64,489  826,057  42,720  237 (5.54)  591 (13.83) 
Naproxen +aspirin  4684  34537  1900  16 (8.42)  24 (12.63) 
Abbreviations: yrs= years; p-yrs=patient-years; GI= gastrointestinal; AMI= acute myocardial infarction. 
 
 
Table 4.  Association Between Naproxen vs Acetaminophen Utilisation and Hospitalization for GI and AMI Adverse Events- Cox-
Regression Models with Time Dependent Exposure 
 
AMI Hospitalizations  GI Hospitalizations   
Study 1  Study 2  Study 1  Study 2 
HR (95% CI) 
Acetamin.  1 (reference)  1 (reference)  1 (reference)  1 (reference) 
Naproxen  0.94 (0.70,1.25)  1.18 (0.83,1.67)  2.22 (1.62,3.06)  4.94 (3.48,7.02) 
Acetamin.+ aspirin  1.10 (0.97,1.26)  1.15 (1.01,1.30)  1.46 (1.20,1.77)  2.31 (1.89, 2.82) 
Naproxen + aspirin  1.05 (0.68,1.61)  1.44 (0.95, 2.18)  2.47(1.48,4.12)  4.94 (2.93, 8.33) 
The models adjusted for all patient characteristics that appear in Table 1. Naproxen-Associated Adverse Events  The Open Rheumatology Journal, 2009, Volume 3    7 
database such as use of non-prescription aspirin or ibuprofen 
and a history of GI events prior to the period examined in 
this study, however, these variables are not expected to differ 
between the two studies and although there is a possibility 
that they may have biased the results in each study toward 
the null, they were unlikely responsible for the change in HR 
observed between the two studies. 
  In conclusion, our study shows that estimates of the risk 
of medication-related adverse events may differ with differ-
ences in study populations. 
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